Multivalent recombinant OspA Lyme Borreliosis Vaccine + Multivalent recombinant OspA Lyme Borreliosis Vaccine + Multivalent recombinant OspA Lyme Borreliosis Vaccine
Phase 1/2Completed 0 views this week 0 watching💤 Quiet
Interest: 29/100
29
Development Stage
✓
Pre-clinical2
Phase 13
Phase 24
Phase 35
ApprovedIndication / Disease
Prophylaxis of Lyme Borreliosis
Conditions
Prophylaxis of Lyme Borreliosis
Trial Timeline
Mar 1, 2011 → Feb 28, 2014
NCT ID
NCT01504347About Multivalent recombinant OspA Lyme Borreliosis Vaccine + Multivalent recombinant OspA Lyme Borreliosis Vaccine + Multivalent recombinant OspA Lyme Borreliosis Vaccine
Multivalent recombinant OspA Lyme Borreliosis Vaccine + Multivalent recombinant OspA Lyme Borreliosis Vaccine + Multivalent recombinant OspA Lyme Borreliosis Vaccine is a phase 1/2 stage product being developed by Baxter for Prophylaxis of Lyme Borreliosis. The current trial status is completed. This product is registered under clinical trial identifier NCT01504347. Target conditions include Prophylaxis of Lyme Borreliosis.
What happened to similar drugs?
2 of 13 similar drugs in Prophylaxis of Lyme Borreliosis were approved
Approved (2) Terminated (2) Active (10)
Hype Score Breakdown
Clinical
9
Activity
8
Company
12
Novelty
0
Community
0
Clinical Trials (1)
| NCT ID | Phase | Status |
|---|---|---|
| NCT01504347 | Phase 1/2 | Completed |
Competing Products
20 competing products in Prophylaxis of Lyme Borreliosis